The programmed death 1/programmed death ligand 1 inhibitory pathway is up-regulated in rheumatoid synovium and regulates peripheral T cell responses in human and murine arthritis

Arthritis and Rheumatism

Volumn 62, Issue 7, 2010, Pages 1870-1880

  Raptopoulou, Amalia P ^a   Bertsias, George ^a   Makrygiannakis, Dimitrios ^b   Verginis, Panagiotis ^a   Kritikos, Iraklis ^a   Tzardi, Maria ^a   Klareskog, Lars ^b   Catrina, Anca I ^b   Sidiropoulos, Prodromos ^a   Boumpas, Dimitrios T ^a  

^a UNIVERSITY OF CRETE   (Greece)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

COLLAGEN TYPE 2; GAMMA INTERFERON; INTERLEUKIN 17; PROGRAMMED DEATH 1 LIGAND 1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL STIMULATION; DISEASE ASSOCIATION; DISEASE SEVERITY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTERFERON PRODUCTION; LYMPHOCYTE PROLIFERATION; MACROPHAGE; MAJOR CLINICAL STUDY; MONOCYTE; MOUSE; NONHUMAN; OSTEOARTHRITIS; PRIORITY JOURNAL; PROTEIN CROSS LINKING; PROTEIN EXPRESSION; PROTEIN FUNCTION; REGULATORY MECHANISM; RHEUMATOID ARTHRITIS; SYNOVIAL FLUID; SYNOVIUM; T LYMPHOCYTE; UPREGULATION;

AGED; ANIMALS; ANTIGENS, CD; ANTIGENS, CD80; ANTIGENS, SURFACE; APOPTOSIS REGULATORY PROTEINS; ARTHRITIS, EXPERIMENTAL; ARTHRITIS, RHEUMATOID; FEMALE; FLOW CYTOMETRY; HUMANS; INTERFERON-GAMMA; LYMPHOCYTE ACTIVATION; MALE; MEMBRANE GLYCOPROTEINS; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MIDDLE AGED; OSTEOARTHRITIS; PEPTIDES; RECOMBINANT PROTEINS; SYNOVIAL MEMBRANE; T-LYMPHOCYTES; UP-REGULATION;

EID: 77954220941     PISSN: 00043591     EISSN: 15290131     Source Type: Journal    
DOI: 10.1002/art.27500     Document Type: Article

References (49)

1. Feldmann M, Brennan F, Maini R. Rheumatoid arthritis. Cell 1996;85:307-10.
2. Firestein GS. Evolving concepts of rheumatoid arthritis. Nature 2003;423:356-61.
3. Lundy SK, Sarkar S, Tesmer LA, Fox DA. Cells of the synovium in rheumatoid arthritis: T lymphocytes. Arthritis Res Ther 2007;9:202.
4. Bennett JC. The role of T lymphocytes in rheumatoid arthritis and other autoimmune diseases. Arthritis Rheum 2008;58 Suppl 2:S53-7.
5. Joosten LA, Abdollahi-Roodsaz S, Heuvelmans-Jacobs M, Helsen MM, van den Bersselaar LA, Oppers-Walgreen B, et al. T cell dependence of chronic destructive murine arthritis induced by repeated local activation of Toll-like receptor-driven pathways: crucial role of both interleukin-1β and interleukin-17. Arthritis Rheum 2008;58:98-108.
6. Klareskog L, Catrina AI, Paget S. Rheumatoid arthritis. Lancet 2009;373:659-72.
7. McInnes IB, Schett G. Cytokines in the pathogenesis of rheumatoid arthritis. Nat Rev Immunol 2007;7:429-42.
8. Holmdahl R, Jansson L, Larsson A, Jonsson R. Arthritis in DBA/1 mice induced with passively transferred type II collagen immune serum: immunohistopathology and serum levels of anti-type II collagen auto-antibodies. Scand J Immunol 1990;31:147-57.
9. Holmdahl R, Klareskog L, Rubin K, Bjork J, Smedegard G, Jonsson R, et al. Role of T lymphocytes in murine collagen induced arthritis. Agents Actions 1986;19:295-305.
10. Chiocchia G, Boissier MC, Ronziere MC, Herbage D, Fournier C. T cell regulation of collagen-induced arthritis in mice. I. Isolation of type II collagen-reactive T cell hybridomas with specific cytotoxic function. J Immunol 1990;145:519-25.
11. Rosloniec EF, Cremer M, Kang A, Myers LK. Collagen-induced arthritis. Curr Protoc Immunol 2001;Chapter 15:Unit 15.5.
12. Williams RO. Collagen-induced arthritis in mice. Methods Mol Med 2007;136:191-9.
13. Greenwald RJ, Freeman GJ, Sharpe AH. The B7 family revisited. Annu Rev Immunol 2005;23:515-48.
14. Fife BT, Pauken KE, Eagar TN, Obu T, Wu J, Tang Q, et al. Interactions between PD-1 and PD-L1 promote tolerance by blocking the TCR-induced stop signal. Nat Immunol 2009;10:1185-92.
15. Parry RV, Chemnitz JM, Frauwirth KA, Lanfranco AR, Braunstein I, Kobayashi SV, et al. CTLA-4 and PD-1 receptors inhibit T-cell activation by distinct mechanisms. Mol Cell Biol 2005;25:9543-53. (Pubitemid 41507854)
16. Sheppard KA, Fitz LJ, Lee JM, Benander C, George JA, Wooters J, et al. PD-1 inhibits T-cell receptor induced phosphorylation of the ZAP70/CD3ξ signalosome and downstream signaling to PKCθ. FEBS Lett 2004;574:37-41. (Pubitemid 39200891)
17. Keir ME, Butte MJ, Freeman GJ, Sharpe AH. PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol 2008;26:677-704. (Pubitemid 351600389)
18. Keir ME, Liang SC, Guleria I, Latchman YE, Qipo A, Albacker LA, et al. Tissue expression of PD-L1 mediates peripheral T cell tolerance. J Exp Med 2006;203:883-95.
19. Martin-Orozco N, Wang YH, Yagita H, Dong C. Cutting edge: programmed death (PD) ligand-1/PD-1 interaction is required for CD8+ T cell tolerance to tissue antigens. J Immunol 2006;177:8291-5. (Pubitemid 44893788)
20. -/- mice as an efficient animal model of type 1 diabetes. Proc Natl Acad Sci U S A 2005;102:11823-8.
21. Okazaki T, Honjo T. The PD-1-PD-L pathway in immunological tolerance. Trends Immunol 2006;27:195-201.
22. Alarcon-Riquelme ME. The genetics of shared autoimmunity. Autoimmunity 2005;38:205-8.
23. Bertsias GK, Nakou M, Choulaki C, Raptopoulou A, Papadimitraki E, Goulielmos G, et al. Genetic, immunologic, and immunohistochemical analysis of the programmed death 1/programmed death ligand 1 pathway in human systemic lupus erythematosus. Arthritis Rheum 2009;60:207-18.
24. James ES, Harney S, Wordsworth BP, Cookson WO, Davis SJ, Moffatt MF. PDCD1: a tissue-specific susceptibility locus for inherited inflammatory disorders. Genes Immun 2005;6:430-7. (Pubitemid 43090519)
25. Kong EK, Prokunina-Olsson L, Wong WH, Lau CS, Chan TM, Alarcon-Riquelme M, et al. A new haplotype of PDCD1 is associated with rheumatoid arthritis in Hong Kong Chinese. Arthritis Rheum 2005;52:1058-62.
26. Lee SH, Lee YA, Woo DH, Song R, Park EK, Ryu MH, et al. Association of the programmed cell death 1 (PDCD1) gene polymorphism with ankylosing spondylitis in the Korean population. Arthritis Res Ther 2006;8:R163.
27. Pearce SH, Merriman TR. Genetic progress towards the molecular basis of autoimmunity. Trends Mol Med 2006;12:90-8.
28. Prevoo ML, van 't Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL. Modified disease activity scores that include twenty-eight-joint counts: development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995;38:44-8.
29. Makrygiannakis D, af Klint E, Catrina SB, Botusan IR, Klareskog E, Klareskog L, et al. Intraarticular corticosteroids decrease synovial RANKL expression in inflammatory arthritis. Arthritis Rheum 2006;54:1463-72.
30. Nishimura H, Nose M, Hiai H, Minato N, Honjo T. Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor. Immunity 1999;11:141-51.
31. Gao W, Demirci G, Strom TB, Li XC. Stimulating PD-1-negative signals concurrent with blocking CD154 co-stimulation induces long-term islet allograft survival. Transplantation 2003;76:994-9.
32. Latchman Y, Wood CR, Chernova T, Chaudhary D, Borde M, Chernova I, et al. PD-L2 is a second ligand for PD-1 and inhibits T cell activation. Nat Immunol 2001;2:261-8.
33. Inglis JJ, Criado G, Medghalchi M, Andrews M, Sandison A, Feldmann M, et al. Collagen-induced arthritis in C57BL/6 mice is associated with a robust and sustained T-cell response to type II collagen. Arthritis Res Ther 2007;9:R113.
34. Bennett F, Luxenberg D, Ling V, Wang IM, Marquette K, Lowe D, et al. Program death-1 engagement upon TCR activation has distinct effects on costimulation and cytokine-driven proliferation: attenuation of ICOS, IL-4, and IL-21, but not CD28, IL-7, and IL-15 responses. J Immunol 2003;170:711-8.
35. Zhong X, Bai C, Gao W, Strom TB, Rothstein TL. Suppression of expression and function of negative immune regulator PD-1 by certain pattern recognition and cytokine receptor signals associated with immune system danger. Int Immunol 2004;16:1181-8. (Pubitemid 39136735)
36. Hatachi S, Iwai Y, Kawano S, Morinobu S, Kobayashi M, Koshiba M, et al. CD4+ PD-1+ T cells accumulate as unique anergic cells in rheumatoid arthritis synovial fluid. J Rheumatol 2003;30:1410-9. (Pubitemid 36835433)
37. Wan B, Nie H, Liu A, Feng G, He D, Xu R, et al. Aberrant regulation of synovial T cell activation by soluble costimulatory molecules in rheumatoid arthritis. J Immunol 2006;177:8844-50. (Pubitemid 44893851)
38. Panayi GS, Lanchbury JS, Kingsley GH. The importance of the T cell in initiating and maintaining the chronic synovitis of rheumatoid arthritis [editorial]. Arthritis Rheum 1992;35:729-35.
39. Liu MF, Kohsaka H, Sakurai H, Azuma M, Okumura K, Saito I, et al. The presence of costimulatory molecules CD86 and CD28 in rheumatoid arthritis synovium. Arthritis Rheum 1996;39:110-4. (Pubitemid 26036385)
40. Namekawa T, Wagner UG, Goronzy JJ, Weyand CM. Functional subsets of CD4 T cells in rheumatoid synovitis. Arthritis Rheum 1998;41:2108-16. (Pubitemid 29009368)
41. Shimoyama Y, Nagafuchi H, Suzuki N, Ochi T, Sakane T. Synovium infiltrating T cells induce excessive synovial cell function through CD28/B7 pathway in patients with rheumatoid arthritis. J Rheumatol 1999;26:2094-101.
42. Berner B, Wolf G, Hummel KM, Muller GA, Reuss-Borst MA. Increased expression of CD40 ligand (CD154) on CD4+ T cells as a marker of disease activity in rheumatoid arthritis. Ann Rheum Dis 2000;59:190-5.
43. Okamoto T, Saito S, Yamanaka H, Tomatsu T, Kamatani N, Ogiuchi H, et al. Expression and function of the co-stimulator H4/ICOS on activated T cells of patients with rheumatoid arthritis. J Rheumatol 2003;30:1157-63. (Pubitemid 36666335)
44. Ruth JH, Rottman JB, Kingsbury GA, Coyle AJ, Haines GK III, Pope RM, et al. ICOS and B7 costimulatory molecule expression identifies activated cellular subsets in rheumatoid arthritis. Cytometry A 2007;71:317-26.
45. Carter LL, Leach MW, Azoitei ML, Cui J, Pelker JW, Jussif J, et al. PD-1/PD-L1, but not PD-1/PD-L2, interactions regulate the severity of experimental autoimmune encephalomyelitis. J Neuroimmunol 2007;182:124-34.
46. Goeb V, Buch MH, Vital EM, Emery P. Costimulation blockade in rheumatic diseases: where we are? Curr Opin Rheumatol 2009;21:244-50.
47. Vincenti F, Luggen M. T cell costimulation: a rational target in the therapeutic armamentarium for autoimmune diseases and transplantation. Annu Rev Med 2007;58:347-58. (Pubitemid 46706519)
48. Dudler J, Li J, Pagnotta M, Pascual M, von Segesser LK, Vassalli G. Gene transfer of programmed death ligand-1.Ig prolongs cardiac allograft survival. Transplantation 2006;82:1733-7.
49. Ozkaynak E, Wang L, Goodearl A, McDonald K, Qin S, O'Keefe T, et al. Programmed death-1 targeting can promote allograft survival. J Immunol 2002;169:6546-53.